Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sunshine Biopharma Inc. - Common stock (NQ:SBFM)

1.910 -0.340 (-15.11%)
Streaming Delayed Price Updated: 2:57 PM EDT, Apr 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sunshine Biopharma Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Sunshine Biopharma Inc. Announces Closing of $2.46 Million Registered Direct Offering
Via ACCESS Newswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Sunshine Biopharma Inc. Announces $2.46 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules
Via ACCESS Newswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Sunshine Biopharma Announces Publication of Significant Coronavirus Research Results in the Journal of Medicinal Chemistry
Via ACCESSWIRE
Sunshine Biopharma Stock Shoots Higher On Encouraging Data From mRNA-Based Liver Cancer Drug
Sunshine Biopharma's K1.1 mRNA-LNP shows promise for HCC treatment in mice, while its 2024 revenue surged 45% to $34.9 million. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Sunshine Biopharma Announces Positive Results of mRNA Therapy for Cancer
Via ACCESS Newswire
US Stock Futures Slip Ahead Of 'Liberation Day' Tariffs Announcement: Expert Points To Uncertainty Amid Higher Risk Premia
U.S. stock futures slipped on Wednesday after a mixed session on Tuesday. Futures of major benchmark indices were lower in premarket trading. 
Via Benzinga
Why Sportsman's Warehouse Shares Are Trading Higher By Around 39%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Sunshine Biopharma Reports Revenue of $34.9M in Fiscal 2024, Up 45% From Last Year
Via ACCESS Newswire
Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada
Via ACCESS Newswire
Sunshine Biopharma Acquires Rights to Launch Two Gastrointestinal Drugs in the Canadian $200 Million Market
Via ACCESS Newswire
Sunshine Biopharma Expands Its Product Line to 69 Generic Prescription Drugs by Launching Olanzapine and Olanzapine ODT
Via ACCESS Newswire
Sunshine Biopharma Announces the Appointment of New Chief Commercial Officer
Via ACCESSWIRE
Sunshine Biopharma Announces Novel Inhibitor for Sars Coronavirus
Via ACCESSWIRE
Sunshine Biopharma Launches a New Generic Prescription Drug
Via ACCESSWIRE
Sunshine Biopharma Announces Breakthrough Research Results on the Company’s K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular Carcinoma
Via ACCESSWIRE
Sunshine Biopharma Launches a New Generic Prescription Drug
Via ACCESSWIRE
Sunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54%
Via ACCESSWIRE
Sunshine Biopharma Launches Two New Generic Prescription Drugs
Via ACCESSWIRE
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:NVAX),(NASDAQ:RGNX),(NASDAQ:BNTX),(NYSE:ABBV) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
From FN Media Group LLC
Via GlobeNewswire
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NYSE:PFE),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
From FN Media Group LLC
Via GlobeNewswire
SUNSHINE BIOPHARMA ANNOUNCES PUBLICATION OF SIGNIFICANT CORONAVIRUS RESEARCH RESULTS IN THE JOURNAL OF MEDICINAL CHEMISTRY
Current Test Positivity Rate for Coronavirus Infection in the U.S. is 18% Development of a novel antiviral compound, XR8-23 (Compound 10), targeting SARS-CoV-2 papain-like protease (PLpro) with both... 
Via FinancialNewsMedia
Exposures COVID-19
Sunshine Biopharma Has Launched Nine New Generic Prescription Drugs in 2024: Now Marketing Sixty-One Generic Drugs in Canada
Via ACCESSWIRE
Sunshine Biopharma Reports 2024 Second Quarter Results: Second QTR Revenues up 67%, YTD Revenues up 61%
Via ACCESSWIRE
SBFM Stock Earnings: Sunshine Biopharma Misses EPS, Beats Revenue for Q2 2024
SBFM stock results show that Sunshine Biopharma missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Sunshine Biopharma Announces Reverse Stock Split
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.